

OMB APPROVAL	
OMB Number:	3235-0104
Expires:	December 31, 2014
Estimated average burden hours per response	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Malik Fady Ibrahim <hr/> (Last) (First) (Middle) 280 EAST GRAND AVENUE <hr/> (Street) SOUTH SAN FRANCISCO CA 94080 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/01/2012	3. Issuer Name and Ticker or Trading Symbol CYTOKINETICS INC [CYTK]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) SVP Research & Early Dev	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned			
1. Title of Security (Instr. 4)	2. Amount of Securities Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	33,632	D	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares ^M			
Incentive Stock Option (right to buy)	04/05/2012 ⁽¹⁾	03/05/2022	Common Stock	136,434	\$ 1.05	D	
Incentive Stock Option (right to buy)	03/31/2011 ⁽²⁾	02/28/2021	Common Stock	71,298	\$ 1.57	D	
Incentive Stock Option (right to buy)	03/26/2009 ⁽³⁾	02/26/2019	Common Stock	31,669	\$ 1.85	D	
Incentive Stock Option (right to buy)	03/24/2010 ⁽⁴⁾	02/24/2020	Common Stock	44,954	\$ 3.08	D	
Incentive Stock Option (right to buy)	03/29/2008 ⁽⁵⁾	02/28/2018	Common Stock	10,395	\$ 3.37	D	
Incentive Stock Option (right to buy)	03/01/2004 ⁽⁶⁾	03/04/2014	Common Stock	12,500	\$ 6.5	D	
Incentive Stock Option (right to buy)	04/01/2007 ⁽⁷⁾	03/14/2017	Common Stock	17,722	\$ 6.81	D	
Incentive Stock Option (right to buy)	04/01/2006 ⁽⁸⁾	03/15/2016	Common Stock	35,000	\$ 7.04	D	
Incentive Stock Option (right to buy)	04/01/2005 ⁽⁹⁾	03/23/2015	Common Stock	9,000	\$ 7.1	D	
Non-Qualified Stock Option (right to buy)	04/05/2012 ⁽¹⁾	03/05/2022	Common Stock	38,566	\$ 1.05	D	
Non-Qualified Stock Option (right to buy)	03/31/2011 ⁽²⁾	02/28/2021	Common Stock	3,702	\$ 1.57	D	
Non-Qualified Stock Option (right to buy)	03/26/2009 ⁽³⁾	02/26/2019	Common Stock	8,331	\$ 1.85	D	
Non-Qualified Stock Option (right to buy)	03/24/2010 ⁽⁴⁾	02/24/2020	Common Stock	5,046	\$ 3.08	D	
Non-Qualified Stock Option (right to buy)	03/29/2008 ⁽⁵⁾	02/28/2018	Common Stock	8,415	\$ 3.37	D	
Non-Qualified Stock Option (right to buy)	04/01/2007 ⁽⁷⁾	03/14/2017	Common Stock	2,078	\$ 6.81	D	
Restricted Stock Units	⁽¹⁰⁾	⁽¹⁰⁾	Common Stock	175,000	\$ ⁽¹¹⁾	D	

Explanation of Responses:

- When the ISO and NQ dated 03/05/2012 are combined for a total grant of 175,000 shares, the option shall vest and become exercisable as to 3,645 shares on 04/05/2012 and the balance of 171,355 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/05/2016.
- When the ISO and NQ dated 02/28/2011 are combined for a total grant of 75,000 shares, the option shall vest and become exercisable as to 1,562 shares on 03/31/2011 and the balance of 73,438 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/28/2015.
- When the ISO and NQ dated 02/26/2009 are combined for a total grant of 40,000 shares, the option shall vest and become exercisable as to 833 shares on 03/26/09 and the balance of 39,167 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/26/13.
- When the ISO and NQ dated 02/24/2010 are combined for a total grant of 50,000 shares, the option shall vest and become exercisable as to 1,041 shares on 03/24/2010 and the balance of 48,959 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/24/2014.
- When the ISO and NQ dated 02/29/2008 are combined for a total grant of 18,810 shares, the option shall vest and become exercisable as to 391 shares on 03/29/08 and the balance of 18,419 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/29/12.

6. This option is immediately exercisable upon grant and shall vest as to 260 shares on 04/01/04 and the balance of 12,240 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/01/08.
7. When the ISO and NQ dated 03/14/2007 are combined for a total grant of 19,800 shares, the option shall vest and become exercisable as to 412 shares on 04/01/07 and the balance of 19,388 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/01/11.
8. This option shall vest and become exercisable as to 729 shares on 04/01/06 and the balance of 34,271 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/01/10.
9. This option shall vest and become exercisable as to 187 shares on 04/01/05 and the balance of 8,813 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/01/09.
10. The restricted stock units vest in two equal annual installments. Vested shares will be delivered to the reporting person on 9/4/2012 and 9/3/2013.
11. Each restricted stock unit represents a contingent right to receive one share of CYTK common stock.

Fady I. Malik, M.D., Ph.D. 06/07/2012

** Signature of Reporting Date
Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Cytokinetics, Incorporated (the Company), hereby constitutes and appoints Sharon Barbari and Robert I. Blum, and each of them, the undersigned's true and lawful attorney-in-fact to

1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his or her discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
2. do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorney-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4th day of June, 2012.

Signature: /s/Fady I. Malik

Print Name: Fady I. Malik